Royalty and Commercial Payment Purchase Agreements - Palo (Details) $ in Thousands |
Sep. 26, 2019
USD ($)
item
|
Mar. 31, 2023
USD ($)
|
Dec. 31, 2022
USD ($)
|
|---|---|---|---|
| Agreements | |||
| Long-term royalty and commercial payment receivables | $ 73,333 | $ 63,683 | |
| Palo | Royalty Purchase Agreement | |||
| Agreements | |||
| Number of drug candidates | item | 6 | ||
| Payments related to purchase of royalty rights and other commercial payment rights | $ 10,000 | ||
| Long-term royalty and commercial payment receivables | $ 10,000 | ||
| Amount of allowance for credit losses | $ 0 | $ 0 |
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of drug candidates under the terms of the agreement. No definition available.
|
| X | ||||||||||
- Definition Long-term royalty and commercial rights receivables, non current. No definition available.
|
| X | ||||||||||
- Definition Payments related to purchase of royalty rights and other commercial payment rights. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|